Search Results - Chris Atkinson
- Showing 1 - 3 results of 3
-
1
-
2
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled tri... by James W. Denham, Allison Steigler, Chantelle Wilcox, David S. Lamb, David Joseph, Chris Atkinson, John Matthews, Keen‐Hun Tai, Nigel Spry, David Christie, Paul S. Gleeson, Peter B. Greer, Catherine D’Este
Published 2008Artigo -
3
Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial by David Joseph, James W. Denham, Allison Steigler, David S. Lamb, Nigel Spry, John C. Stanley, Tom Shannon, Gillian Duchesne, Chris Atkinson, J. H. Matthews, Sandra Turner, Liz Kenny, David Christie, Keen-Hun Tai, Nirdosh Kumar Gogna, Rachel Kearvell, Judy Murray, Martin A. Ebert, Annette Haworth, Brett Delahunt, Christopher Oldmeadow, John Attia
Published 2020Artigo
Search Tools:
Related Subjects
Internal medicine
Medicine
Radiation therapy
Cancer
Clinical endpoint
Confidence interval
Nuclear medicine
Oncology
Prostate cancer
Randomized controlled trial
Surgery
Urology
Adamantinoma
Ameloblastoma
Androgen deprivation therapy
Antrum
Biochemistry
Brachytherapy
Chemistry
Clinical trial
Dentistry
Doubling time
Hazard ratio
In vitro
Maxilla
Prostate
Prostate-specific antigen
Radiology
Randomization
Stomach